Primary intravitreal bevacizumab (avastin) for diabetic macular edema : Results from the pan-american collaborative retina study group at 6-month follow-up
To report the 6-month anatomic and best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin) in patients with diabetic macular edema (DME). Interventional retrospective multicenter study at 6 centers from 6 countries of patients with DME. We reviewed the clinical...
Gespeichert in:
| Veröffentlicht in: | Ophthalmology (Rochester, Minn.) Minn.), 2007-04, Vol.114 (4), p.743-750 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 750 |
|---|---|
| container_issue | 4 |
| container_start_page | 743 |
| container_title | Ophthalmology (Rochester, Minn.) |
| container_volume | 114 |
| creator | FERNANDO AREVALO, J FROMOW-GUERRA, Jans QUIROZ-MERCADO, Hugo SANCHEZ, Juan G WU, Lihteh MAIA, Mauricio BERROCAL, Maria H SOLIS-VIVANCO, Adriana FARAH, Michel E |
| description | To report the 6-month anatomic and best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin) in patients with diabetic macular edema (DME).
Interventional retrospective multicenter study at 6 centers from 6 countries of patients with DME.
We reviewed the clinical records of 88 consecutive patients (110 eyes) with DME. Seventy-eight eyes of 64 consecutive patients with a minimum follow-up of 6 months and mean age of 59.7+/-9.3 years were included in this analysis.
Patients were treated with at least one intravitreal injection of 1.25 mg or 2.5 mg of bevacizumab and underwent Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and follow-up visits. Repeated-measures analysis of variance was used to compare mean values.
Changes in BCVA, OCT, and FA.
Mean follow-up was 6.31+/-0.81 months (range, 6-9). Sixteen (20.5%) eyes needed a second injection at a mean of 13.8 weeks (range, 4-28), and 6 eyes needed a third injection (7.7%) at a mean of 11.5 weeks (range, 5-20). The mean baseline BCVA was 0.87 (logarithm of the minimum angle of resolution), and the final mean BCVA was 0.6, a difference that was statistically significant (P or =2 ETDRS lines of BCVA, and 3 (3.8%) decreased > or =2 ETDRS lines of BCVA. Mean central macular thickness at baseline by OCT was 387.0+/-182.8 mum and decreased to a mean of 275.7+/-108.3 at end of follow-up (P |
| doi_str_mv | 10.1016/j.ophtha.2006.12.028 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_70334906</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70334906</sourcerecordid><originalsourceid>FETCH-LOGICAL-p154t-423e6fdefa473cfd3de2cb918906d0f202408f91b2512f5383a137d2788e940f3</originalsourceid><addsrcrecordid>eNpF0MuKFTEQBuAginMcfQORbBRddJvb6U67k8EbDCii60N1UvFk6HTaXI6Mr-LLGpgjrmrz8f9VRchTznrO-PD6po_bsRyhF4wNPRc9E_oe2fG9mjo1cnmf7Brj3aAEuyCPcr5hDQ5SPSQXfJSTlkLsyJ8vyQdIt9SvJcHJl4Sw0BlPYPzvGmCmL-EEufj1FXUxUethxuINDWDqAomixQD0Df2KuS4lU5dioOWIdIO1g4DJG1ipicsCc0xQ_Alpagkr0FyqvaU_UqwbhUKHLsS1HFvNssRfXd0ekwcOloxPzvOSfH__7tvVx-7684dPV2-vu60dWzolJA7OogM1SuOstCjMPHE9scEyJ5hQTLuJz2LPhdtLLYHL0YpRa5wUc_KSvLjL3VL8WTGXQ_DZYNt4xVjzYWRSqhbW4LMzrHNAe9jufnf4984Gnp8BZAOLS7Aan_87PbR2LeVfWOqIuQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70334906</pqid></control><display><type>article</type><title>Primary intravitreal bevacizumab (avastin) for diabetic macular edema : Results from the pan-american collaborative retina study group at 6-month follow-up</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>FERNANDO AREVALO, J ; FROMOW-GUERRA, Jans ; QUIROZ-MERCADO, Hugo ; SANCHEZ, Juan G ; WU, Lihteh ; MAIA, Mauricio ; BERROCAL, Maria H ; SOLIS-VIVANCO, Adriana ; FARAH, Michel E</creator><creatorcontrib>FERNANDO AREVALO, J ; FROMOW-GUERRA, Jans ; QUIROZ-MERCADO, Hugo ; SANCHEZ, Juan G ; WU, Lihteh ; MAIA, Mauricio ; BERROCAL, Maria H ; SOLIS-VIVANCO, Adriana ; FARAH, Michel E ; Pan-American Collaborative Retina Study Group</creatorcontrib><description>To report the 6-month anatomic and best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin) in patients with diabetic macular edema (DME).
Interventional retrospective multicenter study at 6 centers from 6 countries of patients with DME.
We reviewed the clinical records of 88 consecutive patients (110 eyes) with DME. Seventy-eight eyes of 64 consecutive patients with a minimum follow-up of 6 months and mean age of 59.7+/-9.3 years were included in this analysis.
Patients were treated with at least one intravitreal injection of 1.25 mg or 2.5 mg of bevacizumab and underwent Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and follow-up visits. Repeated-measures analysis of variance was used to compare mean values.
Changes in BCVA, OCT, and FA.
Mean follow-up was 6.31+/-0.81 months (range, 6-9). Sixteen (20.5%) eyes needed a second injection at a mean of 13.8 weeks (range, 4-28), and 6 eyes needed a third injection (7.7%) at a mean of 11.5 weeks (range, 5-20). The mean baseline BCVA was 0.87 (logarithm of the minimum angle of resolution), and the final mean BCVA was 0.6, a difference that was statistically significant (P<0.0001). Final BCVA analysis by subgroups demonstrated that 32 (41.1%) eyes remained stable, 43 (55.1%) improved > or =2 ETDRS lines of BCVA, and 3 (3.8%) decreased > or =2 ETDRS lines of BCVA. Mean central macular thickness at baseline by OCT was 387.0+/-182.8 mum and decreased to a mean of 275.7+/-108.3 at end of follow-up (P<0.0001). No ocular or systemic adverse events were observed.
Primary intravitreal bevacizumab at doses of 1.25 to 2.5 mg seem to provide stability or improvement in VA, OCT, and FA in DME at 6 months. Follow-up is still short to make any specific treatment recommendations; however, the results appear promising. Evaluation in a multicenter randomized controlled clinical trial with longer follow-up is needed.</description><identifier>ISSN: 0161-6420</identifier><identifier>EISSN: 1549-4713</identifier><identifier>DOI: 10.1016/j.ophtha.2006.12.028</identifier><identifier>PMID: 17398322</identifier><identifier>CODEN: OPHTDG</identifier><language>eng</language><publisher>New York, NY: Elsevier</publisher><subject>Angiogenesis Inhibitors - therapeutic use ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Bevacizumab ; Biological and medical sciences ; Diabetes. Impaired glucose tolerance ; Diabetic Retinopathy - complications ; Diabetic Retinopathy - drug therapy ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Female ; Fluorescein Angiography ; Follow-Up Studies ; Humans ; Injections ; Macular Edema - drug therapy ; Macular Edema - etiology ; Male ; Medical sciences ; Middle Aged ; Miscellaneous ; Ophthalmology ; Ophthalmoscopy ; Retrospective Studies ; Tomography, Optical Coherence ; Treatment Outcome ; Vascular Endothelial Growth Factor A - antagonists & inhibitors ; Visual Acuity ; Vitreous Body</subject><ispartof>Ophthalmology (Rochester, Minn.), 2007-04, Vol.114 (4), p.743-750</ispartof><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18638383$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17398322$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>FERNANDO AREVALO, J</creatorcontrib><creatorcontrib>FROMOW-GUERRA, Jans</creatorcontrib><creatorcontrib>QUIROZ-MERCADO, Hugo</creatorcontrib><creatorcontrib>SANCHEZ, Juan G</creatorcontrib><creatorcontrib>WU, Lihteh</creatorcontrib><creatorcontrib>MAIA, Mauricio</creatorcontrib><creatorcontrib>BERROCAL, Maria H</creatorcontrib><creatorcontrib>SOLIS-VIVANCO, Adriana</creatorcontrib><creatorcontrib>FARAH, Michel E</creatorcontrib><creatorcontrib>Pan-American Collaborative Retina Study Group</creatorcontrib><title>Primary intravitreal bevacizumab (avastin) for diabetic macular edema : Results from the pan-american collaborative retina study group at 6-month follow-up</title><title>Ophthalmology (Rochester, Minn.)</title><addtitle>Ophthalmology</addtitle><description>To report the 6-month anatomic and best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin) in patients with diabetic macular edema (DME).
Interventional retrospective multicenter study at 6 centers from 6 countries of patients with DME.
We reviewed the clinical records of 88 consecutive patients (110 eyes) with DME. Seventy-eight eyes of 64 consecutive patients with a minimum follow-up of 6 months and mean age of 59.7+/-9.3 years were included in this analysis.
Patients were treated with at least one intravitreal injection of 1.25 mg or 2.5 mg of bevacizumab and underwent Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and follow-up visits. Repeated-measures analysis of variance was used to compare mean values.
Changes in BCVA, OCT, and FA.
Mean follow-up was 6.31+/-0.81 months (range, 6-9). Sixteen (20.5%) eyes needed a second injection at a mean of 13.8 weeks (range, 4-28), and 6 eyes needed a third injection (7.7%) at a mean of 11.5 weeks (range, 5-20). The mean baseline BCVA was 0.87 (logarithm of the minimum angle of resolution), and the final mean BCVA was 0.6, a difference that was statistically significant (P<0.0001). Final BCVA analysis by subgroups demonstrated that 32 (41.1%) eyes remained stable, 43 (55.1%) improved > or =2 ETDRS lines of BCVA, and 3 (3.8%) decreased > or =2 ETDRS lines of BCVA. Mean central macular thickness at baseline by OCT was 387.0+/-182.8 mum and decreased to a mean of 275.7+/-108.3 at end of follow-up (P<0.0001). No ocular or systemic adverse events were observed.
Primary intravitreal bevacizumab at doses of 1.25 to 2.5 mg seem to provide stability or improvement in VA, OCT, and FA in DME at 6 months. Follow-up is still short to make any specific treatment recommendations; however, the results appear promising. Evaluation in a multicenter randomized controlled clinical trial with longer follow-up is needed.</description><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Bevacizumab</subject><subject>Biological and medical sciences</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Diabetic Retinopathy - complications</subject><subject>Diabetic Retinopathy - drug therapy</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Female</subject><subject>Fluorescein Angiography</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Injections</subject><subject>Macular Edema - drug therapy</subject><subject>Macular Edema - etiology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Miscellaneous</subject><subject>Ophthalmology</subject><subject>Ophthalmoscopy</subject><subject>Retrospective Studies</subject><subject>Tomography, Optical Coherence</subject><subject>Treatment Outcome</subject><subject>Vascular Endothelial Growth Factor A - antagonists & inhibitors</subject><subject>Visual Acuity</subject><subject>Vitreous Body</subject><issn>0161-6420</issn><issn>1549-4713</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0MuKFTEQBuAginMcfQORbBRddJvb6U67k8EbDCii60N1UvFk6HTaXI6Mr-LLGpgjrmrz8f9VRchTznrO-PD6po_bsRyhF4wNPRc9E_oe2fG9mjo1cnmf7Brj3aAEuyCPcr5hDQ5SPSQXfJSTlkLsyJ8vyQdIt9SvJcHJl4Sw0BlPYPzvGmCmL-EEufj1FXUxUethxuINDWDqAomixQD0Df2KuS4lU5dioOWIdIO1g4DJG1ipicsCc0xQ_Alpagkr0FyqvaU_UqwbhUKHLsS1HFvNssRfXd0ekwcOloxPzvOSfH__7tvVx-7684dPV2-vu60dWzolJA7OogM1SuOstCjMPHE9scEyJ5hQTLuJz2LPhdtLLYHL0YpRa5wUc_KSvLjL3VL8WTGXQ_DZYNt4xVjzYWRSqhbW4LMzrHNAe9jufnf4984Gnp8BZAOLS7Aan_87PbR2LeVfWOqIuQ</recordid><startdate>200704</startdate><enddate>200704</enddate><creator>FERNANDO AREVALO, J</creator><creator>FROMOW-GUERRA, Jans</creator><creator>QUIROZ-MERCADO, Hugo</creator><creator>SANCHEZ, Juan G</creator><creator>WU, Lihteh</creator><creator>MAIA, Mauricio</creator><creator>BERROCAL, Maria H</creator><creator>SOLIS-VIVANCO, Adriana</creator><creator>FARAH, Michel E</creator><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200704</creationdate><title>Primary intravitreal bevacizumab (avastin) for diabetic macular edema : Results from the pan-american collaborative retina study group at 6-month follow-up</title><author>FERNANDO AREVALO, J ; FROMOW-GUERRA, Jans ; QUIROZ-MERCADO, Hugo ; SANCHEZ, Juan G ; WU, Lihteh ; MAIA, Mauricio ; BERROCAL, Maria H ; SOLIS-VIVANCO, Adriana ; FARAH, Michel E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p154t-423e6fdefa473cfd3de2cb918906d0f202408f91b2512f5383a137d2788e940f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Bevacizumab</topic><topic>Biological and medical sciences</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Diabetic Retinopathy - complications</topic><topic>Diabetic Retinopathy - drug therapy</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Female</topic><topic>Fluorescein Angiography</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Injections</topic><topic>Macular Edema - drug therapy</topic><topic>Macular Edema - etiology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Miscellaneous</topic><topic>Ophthalmology</topic><topic>Ophthalmoscopy</topic><topic>Retrospective Studies</topic><topic>Tomography, Optical Coherence</topic><topic>Treatment Outcome</topic><topic>Vascular Endothelial Growth Factor A - antagonists & inhibitors</topic><topic>Visual Acuity</topic><topic>Vitreous Body</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>FERNANDO AREVALO, J</creatorcontrib><creatorcontrib>FROMOW-GUERRA, Jans</creatorcontrib><creatorcontrib>QUIROZ-MERCADO, Hugo</creatorcontrib><creatorcontrib>SANCHEZ, Juan G</creatorcontrib><creatorcontrib>WU, Lihteh</creatorcontrib><creatorcontrib>MAIA, Mauricio</creatorcontrib><creatorcontrib>BERROCAL, Maria H</creatorcontrib><creatorcontrib>SOLIS-VIVANCO, Adriana</creatorcontrib><creatorcontrib>FARAH, Michel E</creatorcontrib><creatorcontrib>Pan-American Collaborative Retina Study Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Ophthalmology (Rochester, Minn.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>FERNANDO AREVALO, J</au><au>FROMOW-GUERRA, Jans</au><au>QUIROZ-MERCADO, Hugo</au><au>SANCHEZ, Juan G</au><au>WU, Lihteh</au><au>MAIA, Mauricio</au><au>BERROCAL, Maria H</au><au>SOLIS-VIVANCO, Adriana</au><au>FARAH, Michel E</au><aucorp>Pan-American Collaborative Retina Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Primary intravitreal bevacizumab (avastin) for diabetic macular edema : Results from the pan-american collaborative retina study group at 6-month follow-up</atitle><jtitle>Ophthalmology (Rochester, Minn.)</jtitle><addtitle>Ophthalmology</addtitle><date>2007-04</date><risdate>2007</risdate><volume>114</volume><issue>4</issue><spage>743</spage><epage>750</epage><pages>743-750</pages><issn>0161-6420</issn><eissn>1549-4713</eissn><coden>OPHTDG</coden><abstract>To report the 6-month anatomic and best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin) in patients with diabetic macular edema (DME).
Interventional retrospective multicenter study at 6 centers from 6 countries of patients with DME.
We reviewed the clinical records of 88 consecutive patients (110 eyes) with DME. Seventy-eight eyes of 64 consecutive patients with a minimum follow-up of 6 months and mean age of 59.7+/-9.3 years were included in this analysis.
Patients were treated with at least one intravitreal injection of 1.25 mg or 2.5 mg of bevacizumab and underwent Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and follow-up visits. Repeated-measures analysis of variance was used to compare mean values.
Changes in BCVA, OCT, and FA.
Mean follow-up was 6.31+/-0.81 months (range, 6-9). Sixteen (20.5%) eyes needed a second injection at a mean of 13.8 weeks (range, 4-28), and 6 eyes needed a third injection (7.7%) at a mean of 11.5 weeks (range, 5-20). The mean baseline BCVA was 0.87 (logarithm of the minimum angle of resolution), and the final mean BCVA was 0.6, a difference that was statistically significant (P<0.0001). Final BCVA analysis by subgroups demonstrated that 32 (41.1%) eyes remained stable, 43 (55.1%) improved > or =2 ETDRS lines of BCVA, and 3 (3.8%) decreased > or =2 ETDRS lines of BCVA. Mean central macular thickness at baseline by OCT was 387.0+/-182.8 mum and decreased to a mean of 275.7+/-108.3 at end of follow-up (P<0.0001). No ocular or systemic adverse events were observed.
Primary intravitreal bevacizumab at doses of 1.25 to 2.5 mg seem to provide stability or improvement in VA, OCT, and FA in DME at 6 months. Follow-up is still short to make any specific treatment recommendations; however, the results appear promising. Evaluation in a multicenter randomized controlled clinical trial with longer follow-up is needed.</abstract><cop>New York, NY</cop><pub>Elsevier</pub><pmid>17398322</pmid><doi>10.1016/j.ophtha.2006.12.028</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0161-6420 |
| ispartof | Ophthalmology (Rochester, Minn.), 2007-04, Vol.114 (4), p.743-750 |
| issn | 0161-6420 1549-4713 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70334906 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Bevacizumab Biological and medical sciences Diabetes. Impaired glucose tolerance Diabetic Retinopathy - complications Diabetic Retinopathy - drug therapy Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Female Fluorescein Angiography Follow-Up Studies Humans Injections Macular Edema - drug therapy Macular Edema - etiology Male Medical sciences Middle Aged Miscellaneous Ophthalmology Ophthalmoscopy Retrospective Studies Tomography, Optical Coherence Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity Vitreous Body |
| title | Primary intravitreal bevacizumab (avastin) for diabetic macular edema : Results from the pan-american collaborative retina study group at 6-month follow-up |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T06%3A34%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Primary%20intravitreal%20bevacizumab%20(avastin)%20for%20diabetic%20macular%20edema%20:%20Results%20from%20the%20pan-american%20collaborative%20retina%20study%20group%20at%206-month%20follow-up&rft.jtitle=Ophthalmology%20(Rochester,%20Minn.)&rft.au=FERNANDO%20AREVALO,%20J&rft.aucorp=Pan-American%20Collaborative%20Retina%20Study%20Group&rft.date=2007-04&rft.volume=114&rft.issue=4&rft.spage=743&rft.epage=750&rft.pages=743-750&rft.issn=0161-6420&rft.eissn=1549-4713&rft.coden=OPHTDG&rft_id=info:doi/10.1016/j.ophtha.2006.12.028&rft_dat=%3Cproquest_pubme%3E70334906%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70334906&rft_id=info:pmid/17398322&rfr_iscdi=true |